Dr. Haverkos completed his bachelor’s degree at Miami University in Ohio. This was followed by receipt of a combined MD/MPH degree at Wright State University in Dayton, Ohio as part of the Boonshoft School of Medicine Physician Leadership Development Program. He moved to the University of Illinois in Chicago for his residency in Internal Medicine.
He then completed his fellowship training in Hematology and Oncology at Ohio State University, where he also completed a Master’s degree in Medical Science and a NIH sponsored post-doctoral fellowship with an emphasis on immunology, virology, biostatistics, and clinical trial design. In 2015 he joined the lymphoma and BMT program at the University of Colorado.
Dr. Haverkos is a principle investigator of multiple early-phase clinical trials. He has published and presented his research at the national and international level. He also serves as a reviewer for a number of medical journals and is a member on multiple professional organizations.
Qualifications and experience
- Cancers, Cancers - Blood and Marrow Transplant, Cancers - Lymphoma, Hematology and Oncology, Internal Medicine
- Languages spoken
Ohio State University Hospital Program (2015)
Wright State University Boonshoft School of Medicine (2009)
University of Illinois College of Medicine at Chicago Program (2012)
Miami University of Ohio (OH) (2003)
Ohio State University, The (2015)
Wright State University (2009)
- Clinical interest for patients
My clinical interests include the treatment and management of lymphoma patients with a specific interest in T-cell lymphomas.
- Research interest for patients
Dr. Haverkos’ research focuses on developing novel management and treatment strategies in aggressive lymphoma subtypes with a focus on mature T and NK cell lymphoproliferative disorders (LPDs), including T-cell lymphomas. He collaborates with multiple laboratories with the goal of improving our understanding on the etiopathogenesis of T and NK/T-cell LPDs.
He aims to translate discoveries grounded in this translational research into early phase clinical trials, which will lead to better patient outcomes. Recently, his research efforts center on identifying markers that prognosticate and predict response to specific therapies. He is also interested in improving clinical practice guidelines for patients with blood cancers.